What targeted therapies are available for Endometrial Cancer

Targeted Therapies for Endometrial Cancer

Targeted therapies are medications designed to attack specific characteristics of cancer cells—like particular genetic mutations or protein markers—rather than attacking all rapidly dividing cells like traditional chemotherapy does. For endometrial cancer, several targeted therapy options have emerged based on your tumor's specific biomarkers.

Key Targeted Therapy Approaches

Immunotherapy (Checkpoint Inhibitors)

These are among the most important advances for endometrial cancer. They work by "releasing the brakes" on your immune system so it can recognize and attack cancer cells.

For Mismatch Repair-Deficient (dMMR) or Microsatellite Instability-High (MSI-H) Tumors:

According to NCCN Guidelines, if your tumor has a mismatch repair deficiency (meaning your cancer cells have trouble fixing DNA errors), you may be eligible for:

• Dostarlimab - FDA-approved as a single agent for advanced or recurrent endometrial cancer with dMMR
• Pembrolizumab - FDA-approved for advanced endometrial cancer, particularly those with MSI-H status
• Durvalumab - FDA-approved for dMMR endometrial cancer

These immunotherapies can be used alone or combined with chemotherapy (carboplatin and paclitaxel) for first-line treatment of advanced disease.

HER2-Targeted Therapy

If your pathology report shows HER2 overexpression (meaning your cancer cells have too much of a protein called HER2):

• Trastuzumab (Herceptin) - typically combined with chemotherapy for HER2-positive uterine serous carcinomas
• Trastuzumab deruxtecan - a newer antibody-drug conjugate showing promise in HER2-expressing endometrial cancers

Hormone Receptor-Targeted Therapies

If your tumor is estrogen receptor (ER) positive, several options exist:

NCCN Guidelines recommend:

• Aromatase inhibitors (letrozole, anastrozole, exemestane) - block estrogen production
• Tamoxifen - blocks estrogen receptors on cancer cells
• CDK4/6 inhibitors combined with hormone therapy:
  • Ribociclib + letrozole
  • Palbociclib + letrozole
  • Abemaciclib + letrozole or fulvestrant

These are typically used for recurrent or metastatic disease in lower-grade endometrioid cancers.

mTOR Inhibitors

• Everolimus - can be combined with letrozole for hormone-responsive tumors

Tyrosine Kinase Inhibitors (TKIs)

• Lenvatinib - FDA-approved in combination with pembrolizumab for advanced endometrial cancer. According to NCCN Guidelines, this combination is now a preferred first-line option for advanced disease.

NTRK-Fusion Targeted Therapy

If your tumor has an NTRK gene fusion (a rare but actionable mutation):

• Larotrectinib or entrectinib - specifically target NTRK-positive tumors

Bevacizumab (Anti-Angiogenesis)

• Works by blocking blood vessel formation that tumors need to grow
• Can be combined with chemotherapy for advanced or recurrent disease

How Doctors Decide Which Targeted Therapy

Your oncologist will typically:

1. Test your tumor for specific biomarkers:

   • Mismatch repair status (dMMR vs. pMMR)
   • Microsatellite instability (MSI-H vs. MSS)
   • HER2 status
   • Estrogen/progesterone receptor status
   • POLE mutations
   • p53 mutations
   • NTRK fusions

2. Consider your disease stage - early-stage vs. advanced/recurrent

3. Evaluate your overall health and ability to tolerate treatment

4. Review clinical trial data showing which combinations work best for your specific tumor profile

Important Questions to Ask Your Oncologist

1. "Has my tumor been tested for mismatch repair deficiency and microsatellite instability?" - These are critical for determining immunotherapy eligibility

2. "What is my tumor's HER2 status, and does that open up any targeted therapy options?"

3. "Is my tumor hormone receptor-positive, and would hormone-targeted therapies be appropriate for me?"

4. "Are there any clinical trials available for my specific tumor type and stage?"

5. "Which targeted therapy approach do you recommend for my case, and why?"

6. "What are the expected side effects, and how will we monitor for them?"

7. "If my tumor becomes resistant to one targeted therapy, what would be the next option?"

Current Treatment Landscape

According to NCCN Guidelines, the treatment approach has evolved significantly. For advanced endometrial cancer, combinations of immunotherapy with chemotherapy are now preferred first-line options, particularly:

• Dostarlimab + chemotherapy
• Pembrolizumab + chemotherapy
• Durvalumab + chemotherapy (with or without maintenance olaparib)
• Lenvatinib + pembrolizumab

The specific choice depends on your tumor's molecular characteristics and your individual clinical situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.